Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma
(MedPage Today) -- PARIS -- Neoadjuvant therapy with cemiplimab (Libtayo) achieved deep pathologic responses in patients with resectable cutaneous squamous cell carcinoma (cSCC), according to research presented here.
Among 79 patients treated...
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news
More News: Cancer & Oncology | Carcinoma | Dermatology | Neoadjuvant Therapy | Skin | Skin Cancer | Squamous Cell Carcinoma